RxDoctor Payments Data

Bi Tadzong-Fomundam, MD

Dermatology · Myrtle Beach, SCNPI 1710148648

Payments from drug & device makers

$5,977in general payments, 2019–2025

Across 189 payments — averaging $31.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • Regeneron Healthcare Solutions, Inc.$794
  • Sun Pharmaceutical Industries Inc.$582
  • Arcutis Biotherapeutics, Inc.$538
  • Sanofi$497
  • Johnson & Johnson$402
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,25488%
  • Education$72212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,977 in reported general payments places this provider in the 65th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$280,728
Medicare patients
717
Services billed
4,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdbryTralokinumab-Ldrm16$63,468
Dupixent PenDupilumab12$45,835
Ketoconazole388$5,442
Triamcinolone Acetonide250$2,326
Clobetasol Propionate38$1,469
Mometasone Furoate90$1,437
Fluorouracil22$1,186
Tacrolimus12$739
Doxycycline Hyclate57$674
Hydrocortisone164$668
ValacyclovirValacyclovir Hcl32$561
Mupirocin69$515
Doxycycline Monohydrate21$295
Ammonium Lactate17$237
Hydroxyzine Hcl38$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$112$63,46816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →